CD20

[Nature Cancer] The authors presented the PROSECO prospective observational study on 457 patients with lymphoma that received two or three COVID-19 vaccine doses and showed undetectable humoral responses following two vaccine doses in 52% of patients undergoing active anticancer treatment.

[Scientific Reports] Investigators characterized the distribution of tumor infiltrating lymphocytes (TILs) and TLSs using CD3, CD4, CD8, CD20 immunohistochemistry in a cohort of 10 eccrine porocarcinoma (EPCs) and 49 EPs.

[British Journal of Clinical Pharmacology] A hematopoietic transit model was developed to describe the joint effects of reducing influx from pro-B cells and accelerating CD20+ B cell depletion in the blood by inebilizumab.

[Basic Research in Cardiology] Researchers established an in vitro iPSC model of anthracycline-induced cardiotoxicity (ACT) from patients with an aggressive form of B-cell lymphoma and examined whether doxorubicin-treated ACT-iPSC cardiomyocytes could recapitulate the clinical features exhibited by patients.

[Journal of Translational Medicine] Investigators performed co-culture assays to examine expression of Th2 cytokines by triple negative breast cancer cells with and without the presence of B cells.

[Cancer Immunology Research] Researchers tested the in vitro effect of different natural killer (NK)-cell engagers, which triggered either NKp46 or NKp30 together with CD16A, and targeted either CD19 or CD20 to induce killing of pediatric B cell precursor acute lymphoblastic leukemia.